You are here

Hikma and Adalvo sign agreement to commercialise allergic rhinitis medication across MENA markets

Aug 27,2022 - Last updated at Aug 27,2022

Hikma Pharmaceuticals PLC. (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Adalvo to commercialise a nasal spray medication used to treat an increasingly prevalent respiratory disease; allergic rhinitis (AR).

The exclusive licensing and supply agreement with Adalvo expands Hikma’s respiratory portfolio in MENA. The licensed product is a combination treatment in a single advanced delivery system that has proven efficacy and safety in treating patients with AR.

This medication will help more patients control their symptoms, with an advantage of a faster onset of action and fewer adverse effects. “Ourlatest agreement with Adalvo aligns with Hikma’s strategy of creating a well-diversified pipeline of high-value products, while further solidifying our commercial presence in MENA.

By partnering with a dynamic and progressive company like Adalvo, we are building on our ongoing commitment to offering patients access to high-quality respiratory medications that actively support their treatment journey towards better health,” said Mazen Darwazah, Hikma’s executive vice chairman and president of MENA.

up
8 users have voted.

Opinion

Newsletter

Get top stories and blog posts emailed to you each day.